Table 12 MHC-II -peptide docking scores of selected helper T-cell epitopes.

From: In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine

Epitope (Type)

DRB1–0101

DRB1–0301

DRB1–0401

DRB1–1101

DRB1–1501

DRB5–0101

Average

C.D*

I.S*

C.D

I.S

C.D

I.S

C.D

I.S

C.D

I.S

C.D

I.S

C.D

I.S

L18–22 (16)

48.841

149

463.013

120

33.772

120

41.410

118

30.990

118

47.773

119

60.966

124

L18–22 (18)

57.344

137

45.1999

125

48.297

125

35.110

125

38.195

125

53.419

125

46.261

127

L195–111 (16)

24.887

136

11.423

136

40.015

136

12.880

136

22.660

136

53.440

136

27.551

136

L195–111 (18)

51.199

136

89.320

136

29.488

136

26.401

136

12.182

136

32.170

136

40.127

136

L1327–342 (16)

40.692

123

44.417

117

139.393

115

73.978

115

28.265

115

70.108

110

66.142

115.8

L1324–342 (18)

54.704

123

62.131

117

39.789

114

14.761

114

21.197

114

156.779

110

56.227

115.3

L1416–430 (16)

47.280

135

166.768

133

55.994

135

12.043

135

13.596

133

40.599

135

56.047

134.3

L1417–431 (18)

131.173

147

47.635

147

35.827

147

51.537

147

20.434

147

88.819

147

62.571

147

L2102–120 (16)

43.581

118

34.194

120

46.564

133

19.9137

129

112.397

149

28.873

118

47.588

127.8

L2100–118 (18)

121.068

146

29.429

130

59.920

128

40.538

128

25.8673

128

41.720

128

53.090

131.3

L259–49 (16)

72.663

116

100.837

110

33.013

116

36.984

116

75.634

116

71.575

166

65.117

115

L2281–297(16)

46.236

139

36.971

139

138.283

139

56.161

139

49.871

139

44.997

139

62.086

139

L2274–290 (18)

62.014

139

58.308

139

146.188

139

36.501

139

41.267

139

61.209

139

67.581

139

  1. *higher rate shows better quality of peptide-MHC interactions.